STAAR Surgical Company
STAAHIGH VELOCITYFILING INTENSITYSTAAR Surgical Company reads as High Velocity (composite 70/100); pressure / disclosure signals dominate the posture this cycle · primary market Life Sciences.
Lens
Disclosed M&A capital (2023–2025)
N/A
vs N/A in 2020–2022
Disclosed transactions
N/A
0/3 active fiscal years in window
Buyer archetype
Selective Buyer
Acquisition use is visible but targeted.
Composite score
70
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $35M disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 36d
- 400 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 34 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 34 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 34 activism filings
- Latest activism 2.4y ago; discounted
Distress Watch
Issuers showing financial-distress filing patterns
- 10-Q 216d stale
- 34 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
- 8 NT late filings
- Latest event 16y ago; heavily discounted
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 400 8-Ks
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $1.2B
- 10-Q 216d ago
- 3 active signals
Capital cadence.
No disclosed M&A capital in the 10-year window.
This issuer has not disclosed material acquisition spend or count in the last ten fiscal years.
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Geographic Expansion25%
- Platform25%
- Horizontal Consolidation25%
- Technology Acquisition25%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- geographic_expansion
- platform
- horizontal_consolidation
- technology_acquisition
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“STAAR Japan is also currently seeking approval from the Japanese regulatory authorities to market in Japan STAAR’s Visian ICL, Collamer IOL and AquaFlow Device”
“STAAR completed the acquisition of the remaining 50% interest in its joint venture Canon Staar, Co., Inc. on December 29, 2007”
“The global nature of STAAR’s business operations subjects it to risks, including the effect of changes in currency exchange rates, differences in laws, including laws protecting intellectual property and regulating medical devices, political risks and the challenge of managing foreign subsidiaries. Our global manufacturing consolidation also exposes us to the risk of unexpected costs and possible supply interruptions. See “Item 1A. Risk Factors —Risks Related to Our Business —The global nature of our business may result in fluctuations and declines in our sales and profits”; “—The success of our international operations depend on our successfully managing our foreign subsidiaries”; “—Non-compliance with anti-corruption laws could lead to penalties or harm our reputation”; and “—We may not realize the expected benefits of our manufacturing consolidation and tax strategies.””
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Life Sciences
- Market spend (2023–2025)
- $68.3B
- Market spend (2020–2022)
- $107.5B
- Recent vs prior
- −36%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
STAA trades at a -48.3-turn discount to the Life Sciences peer median of 16.1×.
- EV / Revenue
- 5.0×
- Net debt / EBITDA
- N/A
- Peer median EV / EBITDA
- 16.1×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
| 19.1× | 4.7× | -0.0× | $45.2B | $10.8B | |
| 18.8× | 4.3× | -0.3× | $20.6B | $8B | |
| 13.3× | 3.5× | -0.1× | $35.5B | $2.2B | |
| 13.1× | 1.9× | -0.2× | $14.1B | $2.1B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Life Sciences. Bars scaled to the highest EV/EBITDA in the set.
Buyer landscape.
Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.
Likely buyers
No public buyers surface as a strong target-side fit on current signal.
Likely sellers / divestiture partners
No reciprocal divestiture / strategic-alternatives matches identified.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)392026-03-03
- 10-Q (quarterly)982025-11-05
- 8-K (event)4002026-04-08
- Proxy / DEF 14A1222026-05-04
- Activism (13D / DFAN / PREC)342024-01-10
Signals on file
- watch
Late-filing notice
2010-03-188 NT 10-K/10-Q filings on file.
- elevated
Activism on file
2024-01-1034 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Restatement risk
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.